DeepMed Research

Kashiv BioSciences, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects

Phase 1

Completed

Conditions: Rheumatoid Arthritis (RA

Interventions: Drug: Abatacept

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Kashiv BioSciences, LLC

Target Recruit Count: 300

Registration Number: NCT06929039

Locations: 🇨🇦
Not Disclosed, Missisauga, Canada

A Open Label ,Randomized, Balanced, Two-treatment, Single Period, Parallel, Comparative Pharmacokinetic Study in Healthy Subjects

Phase 1

Recruiting

Conditions: Chronic Idiopathic Urticaria

Interventions: Device: ADL-018 Autoinjector
Drug: ADL-018 Injection

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Kashiv BioSciences, LLC

Target Recruit Count: 150

Registration Number: NCT06929052

Locations: 🇨🇦
Not Disclosed, Missisauga, Canada

Open Label Randomized Comparative Crossover Pharmacokinetic and Immunogenicity Study

Phase 1

Active, not recruiting

Conditions: Febrile Neutropenia

Interventions: Device: TPI-120 with On body injector
Drug: Fylntera

First Posted Date: 2025-04-09

Last Posted Date: 2025-04-09

Lead Sponsor: Kashiv BioSciences, LLC

Target Recruit Count: 180

Registration Number: NCT06918587

Locations: 🇯🇴
Not Disclosed, Jordan, Jordan

Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Fulvestrant injection

First Posted Date: 2023-10-10

Last Posted Date: 2023-10-10

Lead Sponsor: Kashiv BioSciences, LLC

Target Recruit Count: 48

Registration Number: NCT06074757

Locations: 🇯🇴
Triumpharma Cro, Amman, Jordan

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Phase 3

Completed

Conditions: Chronic Idiopathic Urticaria

Interventions: Drug: Xolair Prefilled Syringe
Drug: Omalizumab Injection

First Posted Date: 2023-03-17

Last Posted Date: 2025-02-05

Lead Sponsor: Kashiv BioSciences, LLC

Target Recruit Count: 600

Registration Number: NCT05774639

Locations: 🇮🇳
Site 001, Mumbai, Maharashtra, India
🇺🇸
True Blue Clinical Research, Brandon, Florida, United States
🇺🇸
Access Research Institute, Brooksville, Florida, United States

and more 3 locations

PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Omalizumab 150mg

First Posted Date: 2022-10-03

Last Posted Date: 2025-02-05

Lead Sponsor: Kashiv BioSciences, LLC

Target Recruit Count: 204

Registration Number: NCT05564611

Locations: 🇮🇳
Registered BE centre, Mahesana, Gujarat, India

To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: EU-Approved XOLAIR
Biological: US-licensed XOLAIR
Biological: ADL-018

First Posted Date: 2022-06-09

Last Posted Date: 2023-07-03

Lead Sponsor: Kashiv BioSciences, LLC

Target Recruit Count: 306

Registration Number: NCT05413161

Locations: 🇮🇳
Registered BABE Centre, Mahesana, Gujarat, India
🇮🇳
Registered BABE centre, Ahmedabad, Gujarat, India

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy